A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia

Table 3 Mortality (28-day) in tifacogin and placebo groups for all patients and by microbiology status and heparin use

	Tifacogin			Placebo			P value
	All	Mortality		All	Mortality
	Number	Number	Percentage	Number	Number	Percentage
All community-acquired pneumonia patients	251	70	27.9	245	80	32.7	0.25
Microbiology status
Organism identified	170	46	27.1	154	55	35.7	0.09
Organism not identified	81	24	29.6	91	25	27.5	0.75
Procalcitonin level
<2	50	15	30.0	60	18	30.0	1.00
≥ 2	200	55	27.5	183	62	33.9	0.18
Heparin use
No Heparin	79	23	29.1	78	33	42.3	0.08
Heparin	172	47	27.3	167	47	28.1	0.87
Microbiology status and heparin use
No heparin/Organism identified	58	17	29.3	54	28	51.9	0.02
No heparin/Organism not identified	21	6	28.6	24	5	20.8	0.54
Shock
Yes	163	50	30.7	176	64	36.4	0.27
No	88	20	22.7	69	16	23.2	0.95
Ventilatory support
Yes	193	60	31.1	200	75	37.5	0.18
No	58	10	17.2	45	5	11.1	0.38
Number of organ dysfunctions
Two or less	87	17	19.5	72	13	18.1	0.81
Three or more	164	53	32.3	173	67	38.7	0.22

ISSN: 1364-8535